Postdoctoral Research Fellow
£27,319-£33,600 per annum (depending on experience and qualifications)
School of Medicine – Cancer Sciences Division
Neuroblastoma is one of the commonest malignancies of childhood. Most children present with widespread disease and despite increasingly high dose therapies, survival from metastatic disease remains poor. More than 60% of this group of children die from their tumour and new, more effective, therapies are needed to improve survival. One new group of agents that show exciting thereputic potential for this disease are immunostimulatory monoclonal antibodies (mAb), that is mAb that stimulate the immune system to generate anti-tumour immunity.
Applications are invited for a post-doctoral research fellow to join an innovative project aimed at investigating a range of different immunostimulatory mAb in pre-clinical models in order to establish how they can best be used to treat neuroblastoma. In particular the project will investigate how this type of mAb can be combined with different types of peptide vaccine (e.g. long peptides) to optimise anti-neuroblastoma immune responses. The project is part of a well-established and productive therapeutic antibody research programme within the Cancer Sciences Division.
You will be enthusiastic, motivated, have research experience in standard biochemical, cell-biological or immunological techniques and hold a PhD.
The position will be full time working with a team of researchers under Dr Juliet Gray and Professor Martin Glennie in the Cancer Sciences Division and will be based at Southampton General Hospital.
The post is full-time and fixed term for 3 years.
The closing date for applications is 18 May 2010 at 12.00 noon.
For more information on this position or to apply online please visit www.jobs.soton.ac.uk. Alternatively please call 023 80 592750. Please quote reference number 4461-10-M.
为防止简历投递丢失请抄送一份至：boshijob@126.com（邮件标题格式：应聘职位名称+姓名+学历+专业+中国博士人才网）
中国-博士人才网发布
声明提示：凡本网注明“来源：XXX”的文/图等稿件，本网转载出于传递更多信息及方便产业探讨之目的，并不意味着本站赞同其观点或证实其内容的真实性，文章内容仅供参考。
